AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03080597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrEP Smart app
Description: English-speaking males, between the ages of 18-30, who are enrolled at a HBCU or identify as Black/African American, who are currently prescribed PrEP (Truvada) for HIV Prevention, and owners of either an Android or iOS smartphone, will be asked to use an application on their smart phones called PrEP Smart.an application on their smart phones called PrEP Smart.
Study NCT02770820 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC
Study NCT02770820 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes
Description: Given IV
Study NCT02770820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04104165 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley Catheter
Description: Foley catheter used for treatment of urinary retention
Study NCT01106001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The placebo group received 60mls of 0.9% saline injected intra-operatively through the medial and anterior capsular spaces in the region of the obturator and femoral nerves and also around the short rotators and gluteus maximus in the region of the inferior and superior gluteal nerves. The timing of this was after insertion of the acetabular component. 10mls was then infiltrated around the tensor fascia lata and subcutaneously prior to closing the wound.
Study NCT03505398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: automated visual field
Description: recording visual attention based on central or peripheral visual information
Study NCT03505398 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: automated visual field
Description: recording visual attention based on central or peripheral visual information
Study NCT00679640 — intervention group
Intervention type: DRUG
Intervention: Candesartan
Description: Oral tablets
Study NCT01402219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iopamidol injection 76%
Description: Iopamiro-370 (Iopamidol injection 76%) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
Study NCT01402219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iodixanol
Description: Visipaque 320 (iodixanol) injection is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
Study NCT02031094 — intervention group
Intervention type: OTHER
Intervention: Observational study: Sense Wear armband and indirect calorimetry used to measure resting energy expenditure
Description: Observational methods of measuring resting energy expenditure
Study NCT02409472 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: surveillance program after completion of primary treatment
Description: These are two different surveillance programs for Dukes B2-C colorectal cancer patients who have no evidence of disease at the end of their front line treatment (surgery and adjuvant radio-chemotherapy, if indicated). These programs differ greatly in the frequency of diagnostic imaging. They had similar schedules of physical examinations and carcinoembryonic antigen (CEA) assessments.
Study NCT02077465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: 400 mg andecaliximab administered intravenously
Study NCT02077465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match Andecaliximab
Description: Placebo to match andecaliximab administered intravenously
Study NCT03505398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: eye movements recording
Description: recording of explicit visual attention based on central or peripheral visual information
Study NCT03505398 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: eye movements recording
Description: recording of explicit visual attention based on central or peripheral visual information
Study NCT03337386 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: inferior vena cava collapsibility
Description: inferior vena cava diameters is obtained in the supine position with a convex probe .The probe is placed in the subxiphoid region or the right anterior midaxillary plane.The sagittal section of IVC is imaged. M-mode probe is used to identify the measurement of minimum and maximum venous dimensions over the respiratory cycle using the 3.5-5 MHz phased array probe. To standardize the measurements, measuring of the IVC diameter is performed at 2 cm caudal of the junction point of the right atrium and IVC. The difference between the maximum (D max) and minimum (D min)diameters of the target vein is normalized according to the standard formula to yield the collapsibility index (CI).
Study NCT03337386 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: subclavian vein collapsibility
Description: Right SCV diameters is checked in the supine position using a high frequency linear array probe (6-13 MHz) and M-mode. To standardize the measurements, the probe is placed beneath the proximal part of the middle part of the clavicle perpendicular to long-axis of the SCV to obtain the best cross-sectional view of the vien. After the target vein is localized , the dynamic diameter change is recorded using M-mode to identify and measure the minimum and maximum venous diameters.To calculate SCV collapsibility index, the standard formula is used.
Study NCT03337386 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: central venous pressure
Description: ultrasound guided 7.5-F central venous catheter is introduced via right internal jugular vein under local analgesia with 2% lidocaine for measuring the CVP.
Study NCT04758130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zamplo Digital Health Platform
Description: This application will be provided to patients and provide them with a method to track various data related to their metabolic disease.
Study NCT04758130 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Zamplo Digital Health Platform
Description: This application will be provided to patients and provide them with a method to track various data related to their metabolic disease.
Study NCT00878878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optison (Perflutren Protein-Type A Microspheres Injectable Suspension)
Description: Arm A: Single intravenous (IV) injection of 0.5 mL Optison followed by single IV injection of 0.5 mL 5% dextrose.~Arm B: Single IV injection of 0.5 mL 5% dextrose followed by single IV injection of 0.5 mL Optison.
Study NCT00878878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: Arm A: Single intravenous (IV) injection of 0.5 mL Optison followed by single IV injection of 0.5 mL 5% dextrose.~Arm B: Single IV injection of 0.5 mL 5% dextrose followed by single IV injection of 0.5 mL Optison.
Study NCT03966365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-122
Description: * PRO-122. Timolol 0.5% / brimonidine 0.2% / dorzolamide 2% ophthalmic solution free of preservatives. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.~* Route of administration: topical ophthalmic.
Study NCT02539706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium 0,6mg/kg
Description: patients at days 8 to 14 of the menstrual cycle were considered to be at the follicular phase and Rocuronium 0,6mg/kg intravenous was applied
Study NCT02539706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium 0,6mg/kg
Description: patients at days 18 to 24 of the menstrual cycle were considered to be at the luteal phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied
Study NCT01243268 — intervention group
Intervention type: DRUG
Intervention: Twynsta tablet
Description: Telmisartan and Amlodipine T40/A5, T80/A5 and T40/A10
Study NCT00716716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFIXFc
Description: As specified in the treatment arm
Study NCT01624142 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab was administered by subcutaneous injection either once a month (QM) or once every two weeks (Q2W).
Study NCT03966365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Krytantek Ofteno®
Description: * - 1. Krytantek Ofteno®. Timolol 0.5% / brimonidine 0.2% / dorzolamide 2% ophthalmic solution. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.~* - Route of administration: topical ophthalmic.
Study NCT01947218 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: bronchial biopsies
Study NCT01947218 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bronchial biopsies
Study NCT01947218 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Determination of CO in exhaled air
Study NCT00831376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levosalbutamol
Description: Patients will be asked to take two puffs four times a day for 2 weeks
Study NCT01947218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Determination of CO in exhaled air
Study NCT00831376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: racemic salbutamol
Description: Patients will be asked to take two puffs four times a day for 2 weeks
Study NCT00831376 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will be asked to take two puffs four times a day for 2 weeks
Study NCT02193789 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: deployment of through the scope covered metallic stent at the stricture site
Description: Deployment of Covered Self-expandable Metallic Stents Insertion fixing with Clips and Suture Material at the stricture site
Study NCT02193789 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Covered Self-expandable Metallic Stents
Study NCT06057311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hippotherapy
Description: The participants in HT Group; received 12 sessions as 2 sessions a week for 6 weeks. Each therapy session lasted for an average of 20 min. The assessments were applied twice to all participants before and after the training. The treatments and assessments were performed by the same physiotherapist in the same environment.
Study NCT01591447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solithromycin
Description: A single oral dose of 1200 mg solithromycin (CEM-101)
Study NCT01591447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solithromycin (CEM-101)
Description: A single oral dose of 1000 mg solithromycin
Study NCT00481338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-rays
Description: X-rays (hip and knee) every 2 years
Study NCT00481338 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biological samples
Description: biological sample (blood and urine) every 2 years
Study NCT00481338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical information about osteoarthritis
Description: several questionnaires about pain and function (WOMAC), physical activity (MAQ), quality of life (generic SF-36 and OA specific OAKHQOL/AMIQUAL), comorbidities (FCI), mental status (MMS), heath status (GHQ 28) and health resource consumption
Study NCT04383366 — intervention group
Intervention type: DEVICE
Intervention: Pentacam® (Oculus, Inc., Wetzlar, Germany)
Description: Scheimpflug imaging
Study NCT04383366 — intervention group
Intervention type: DEVICE
Intervention: Casia II (Tomey Germany, Nürnberg)
Description: Anterior segment optical coherence tomography
Study NCT04383366 — intervention group
Intervention type: DEVICE
Intervention: Spectralis Anterion (Heidelberg Engineering, Heidelberg, Germany)
Description: Anterior segment optical coherence tomography
Study NCT01012635 — intervention group
Intervention type: OTHER
Intervention: Hypnosis
Description: Hypnosis Training: Verbal suggestions from an audio recording (via headphones).
Study NCT01012635 — intervention group
Intervention type: OTHER
Intervention: Meditation
Description: Meditation: focus on a single word (one) for the entire session.
Study NCT01012635 — intervention group
Intervention type: OTHER
Intervention: Neurofeedback training
Description: Neurofeedback Training: Two electrodes will be placed on your scalp, and one electrode clipped on your head. There is no risk of electrical shock.
Study NCT01012635 — intervention group
Intervention type: OTHER
Intervention: Two different levels of tDCS
Description: Direct stimulation of the brain by using a weak electrical current. There is no risk of electrical shock.
Study NCT02583763 — intervention group
Intervention type: OTHER
Intervention: Echocardiography
Description: During the ultrasound examinations standardized, moving sequences of the heart will be saved. Analyzes are performed off-line and analyzed by vector velocity imaging software.
Study NCT02583763 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample
Description: The investigators will take a blood sample from the umbilical cord at birth and again at 7 years of age.
Study NCT06057311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Equine-Assisted Activities Therapy
Description: The participants in the EAAT Group received 12 sessions as 2 sessions a week for 6 weeks. Each therapy session lasted for an average of 20 min. The assessments were applied twice to all participants before and after the training. The treatments and assessments were performed by the same physiotherapist in the same environment.
Study NCT01654458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GyneGals Support Group
Description: 12-week online (i.e. Internet-based), professionally-facilitated support group
Study NCT03233724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine (DAC)
Description: Administered orally on two consecutive days (preferably Tuesday and Wednesday) for two weeks out of three weeks x 9 weeks
Study NCT03233724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrouridine (THU)
Description: Administered orally on two consecutive days (preferably Tuesday and Wednesday) for two weeks out of three weeks x 9 weeks
Study NCT03233724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg intravenous (IV) once a day every Wednesday, Thursday or Friday every 3 weeks.
Study NCT04065035 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Topical Body Firming Moisturizer
Description: Moisturizer composed of a patent-pending blend of botanical extracts, bioavailable peptides, antioxidants, and a prebiotic innovation
Study NCT04065035 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Body Cleanser
Description: Body cleanser to be used by study participants
Study NCT04065035 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Body Cleanser
Description: Body cleanser to be used by study participants
Study NCT04065035 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sunscreen
Description: Sunscreen to be applied after application of moisturizer
Study NCT04065035 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen
Description: Sunscreen to be applied after application of moisturizer
Study NCT04065035 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Moisturizer
Description: Placebo moisturizer is the vehicle control of the topical body firming moisturizer
Study NCT04270448 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motor Sequence Task
Description: Participants will be seated at a laptop with the right hand on a standard joystick. The movement of the joystick will move a cursor on the computer screen. Targets will appear on the laptop screen as a circle in one of twelve spatially distinct locations. The learner must move the joystick cursor to inside the target before the next target will appear.
Study NCT04270448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Sequence Task
Description: Participants will be seated at a laptop with the right hand on a standard joystick. The movement of the joystick will move a cursor on the computer screen. Targets will appear on the laptop screen as a circle in one of twelve spatially distinct locations. The learner must move the joystick cursor to inside the target before the next target will appear.
Study NCT00496964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A + exercise
Description: Injection of 100 units Botox (Botulinum toxin type A) into the Vastus Lateralis of the study leg + 12 weeks of exercise for patellofemoral pain
Study NCT00496964 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of 2 cc placebo containing 0.1cc sodium bicarbonate 8.4% (1meq/cc), 0.9cc normal saline and 1 cc of lidocaine into the vastus lateralis of the study leg followed by 12 weeks of exercise for patellofemoral pain syndrome
Study NCT01287910 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cardiac MRI
Description: Cardiac MRI within 30 days prior to TMR procedure and 6 months after TMR procedure.
Study NCT02301910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant staphylokinase
Description: 15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
Study NCT00509262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Participants with moderate renal insufficiency will receive two sitagliptin 25 mg tablets orally daily; participants with severe renal insufficiency will receive one sitagliptin 25 mg tablet orally daily
Study NCT00509262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glipizide
Description: Participants will receive glipizide 2.5 mg (1/2 tablet) orally once daily up to 20 mg orally daily (10 mg twice daily)
Study NCT00509262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Sitagliptin
Description: Participants with moderate renal insufficiency will receive 2 placebo for sitagliptin tablets orally daily; participants with severe renal insufficiency will receive 1 placebo for sitagliptin tablet orally daily
Study NCT00509262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Glipizide
Description: Participants will receive 1/2 tablet of placebo for glipizide orally once daily up to 2 tablets orally twice daily
Study NCT02454361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-7072
Description: KBP-7072
Study NCT02454361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT00402233 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pramipexole
Study NCT06057311 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The Control Group (CG) did not receive any training. The assessments were applied twice to CG at baseline and after 6 weeks. The treatments and assessments were performed by the same physiotherapist in the same environment.
Study NCT04114305 — intervention group
Intervention type: BEHAVIORAL
Intervention: ECD Intervention
Description: Modeled on the Early Learning Resource Unit's Family \& Community Motivator home visiting program and Philani Mentor Mothers home visiting program in South Africa. Program provided stimulation in 5 domains: cognitive, receptive and expressive language, gross and fine motor skills, also covered topics in maternal and child health, nutrition and social services.~Comprised primarily of home visits beginning during pregnancy and continuing until the child was 18 months. ECD MM taught the parent/caregiver about ages and stages of growth, helped facilitate responsive parenting and early learning opportunities for their children, demonstrated use of toys and books to stimulate the child, provided families with picture books, and taught caregivers to create toys and books for their child. Community parenting information play groups and educational talks on ECD at the clinic supplemented home visits.
Study NCT04723095 — intervention group
Intervention type: OTHER
Intervention: Follow-Up
Description: Receive follow up
Study NCT02301910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenecteplase
Description: 50 mg of drug reconstituted in 10 ml sterile water for injection given as single weight-adjusted i.v. bolus over 5 - 10 seconds Weight (kg) Dose (mg) Dose (ml)~* 55 to \<60 30 mg 6 ml~* 60 to \<70 35 mg 7 ml~* 70 to \<80 40 mg 8 ml
Study NCT04723095 — intervention group
Intervention type: OTHER
Intervention: Medical Chart Review
Description: Review of medical records
Study NCT02145130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: denovoDerm
Description: Transplantation of an autologous tissue-engineered dermal substitute, covered with autologous split-thickness skin
Study NCT02145130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: denovoSkin
Description: Transplantation of autologous tissue-engineered dermo-epidermal skin substitute, no additional coverage needed
Study NCT01757600 — intervention group
Intervention type: OTHER
Intervention: Microperimetry
Study NCT03638739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Twice-weekly exercise
Description: An individualized exercise plan, incorporating aerobic and resistance exercises, following the Physical Activity Guideline recommendations will be provided for each participant.
Study NCT02426762 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Description: Various laparoscopic operations are performed for participants. Once all surgical procedures are successfully applied, surgical wounds which are associated with laparoscopic surgery would be sealed by a quick sealant. In all, the following surgical wounds would be left:~* 4-5 trocar-produced incisions (5/10mm, minor incision)~* 1 sample-retrieval incision (4-5cm, small incision)